Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Moderately Reduced Carbohydrate Diet Keeps People Feeling Full Longer
A modest reduction in the amount of carbohydrates eaten, without calorie restriction and weight loss, appears to increase a sense of fullness, which may help people eat less, a preliminary study found. The results were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.

CFIA And USDA Revise Potato Cyst Nematode Guidelines
The Canadian Food Inspection Agency (CFIA) and the United States Department of Agriculture (USDA) today announced revised guidelines for potato cyst nematode (PCN) that will allow continued trade of seed potatoes between the two countries. While PCN does not pose a risk to human health, it is recognized internationally as a destructive plant pest of economic importance and, therefore, a quarantine pest for the United States and Canada.
News of the day
CEL-SCI Files Patent Application To Support Company's Treatment For More Virulent Strain Of H1N1 Swine And Other Influenza Viruses
CEL-SCI CORPORATION (NYSE AMEX: CVM) announced that it has filed a provisional U.S. patent application covering its L.E.A.P.S.(TM) immune therapy drugs (vaccines) for the prevention/treatment of H1N1, swine, bird flu, Influenza A and/or evolving mutants or variants of these viruses. Some experts believe that by the next flu season the swine flu virus will have evolved and/or combined with other viruses to create a much more lethal new virus. That is what happened in the case of the Spanish flu pandemic. CEL-SCI"s efforts to fight this virus are focused on using conserved epitopes from essential proteins to be found in the A influenza virus for H1N1, H1N5, swine, bird flu and Spanish influenza to create an effective vaccine/treatment that could potentially fight such a mutant virus.
Medical Devices

European Urology July Issue Reviews Prostate Screening Studies

The July issue of European Urology, the official journal of the European Association of Urology, features an editorial by Lars Holmberg comparing the results from the European Randomised Study of Screening for Prostate Cancer (ERSPC) with the results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) In the editorial, Professor Holmberg writes that "The studies illustrate that the price to pay for 20% reduction in prostate cancer deaths is high; overdiagnosis and overtreatment are great problems. The answers lie in improving the PSA test or finding biomarkers that effectively separate aggressive cancers from slow-growing ones. We identify some priorities in the discussion about PSA testing." Another article of interest in this issue is "Testosterone and Prostate Cancer: Revisiting Old Paradigms" by H. Isbarn et al. The notion that pathologic prostate growth, benign or malignant, can be stimulated by androgens is a commonly held belief - but one without scientific basis. In the article, Dr. Isbarn writes that, "We therefore conducted a Medline search to identify articles addressing the relationship between testosterone and the risk of prostate cancer development. Although large prospective studies addressing the long-term effect of testosterone treatment are needed to either refute or corroborate the hypothesis, the available literature strongly suggests that testosterone treatment neither increases the risk of prostate cancer diagnosis in normal men nor causes cancer recurrence in men who were successfully treated for prostate cancer." Next month, European Urology will publish the EAU position statement on screening for prostate cancer which takes into consideration the recent scientific information on randomised screening studies on prostate cancer (Schrç¶der et al, NEJM 2009). The EAU adopts the conclusions of the ERSPC study and recognises the benefit of screening in terms of mortality reduction, as well as the adverse effects of overdiagnosis and overtreatment of prostate cancers which could be quantified for the first time in the setting of a randomised screening study. Lindy Brouwer European Association of Urology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009